Emboline Secures Funding for Commercialization of Emboliner Embolic Protection System

March 13, 2026—Emboline, Inc., announced it has closed $20 million in growth capital that will support preparations for the commercial introduction of the company’s Emboliner embolic protection system while continuing development of additional technologies designed to reduce embolic risk during structural heart interventions.

According to the company, the Emboliner device is designed to provide full cerebral and systemic embolic protection by capturing and removing embolic debris released during transcatheter heart procedures.

The press release noted that Emboline recently completed enrollment in the prospective, randomized PROTECT H2H investigational device exemption (IDE) clinical trial evaluating the Emboliner system. Results from the study will be presented on March 29, 2026, in a late-breaking clinical trial session at ACC.26, the American College of Cardiology’s annual scientific sessions.

The funding was provided by Trinity Capital, an alternative asset manager.

“We are excited to partner with Trinity Capital at a pivotal moment for Emboline,” stated Scott Russell, President and CEO of Emboline, in the press release. “With the completion of our IDE clinical trial and regulatory submissions ahead, this financing positions us to prepare for commercial launch in the United States and Europe later this year. Our goal is to provide physicians with a comprehensive embolic protection solution that helps reduce stroke and ischemic injury during transcatheter procedures.”